Addiction Research

According to the World Health Organization (WHO), addiction is 'a chronic disease of the central nervous system that is characterized by a loss of control over impulsive behavior that leads to compulsive drug seeking and taking, and to relapses even after months of abstinence'. Addiction is a complex neuroadaptive process, where drugs of abuse alter cellular and molecular aspects of neural function. The brain circuits mediating the various behavioral effects of these drugs are rendered more, or less, responsive to those effects.

Addiction Research Products Targets

Products for Addiction Research - Page 41

Cat.No. Product Name Information/Activity
BCC4904 Felbamate Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).
BCC7340 Gavestinel 153436-38-5
BCC6589 (S)-(-)-HA-966 111821-58-0
BCC5946 HU 211 Dexanabinol (HU-211) is an artificially synthesized cannabinoid derivative and lacks cannabimimetic effects. Dexanabinol exhibits not only the antioxidant and neuroprotective activities in brain but also anti-inflammatory activity by inhibiting NF-κB and decreasing cytokines such as TNFα and interleukin-6, which could ensure the integrity of BBB and reduce cell apoptosis and death. Dexanabinol is widely used in head injury or stroke treatment and has been shown to be safe in animals and humans.
BCC6594 N-(4-Hydroxyphenylacetyl)spermine 130210-32-1
BCC6688 Ifenprodil hemitartrate 23210-56-2
BCC7508 threo Ifenprodil hemitartrate 1312991-83-5
BCC5982 Ketamine hydrochloride 1867-66-9
BCC7930 (S)-(+)-Ketamine hydrochloride 33643-47-9
BCC6774 L-689,560 L-689560 is a potent N-methyl-D-aspartate (NMDA) receptor antagonist at the GluN1 glycine binding site. L-689560 is widely used as a radiolabeled ligand in binding studies and used for study the roles of NMDA receptors in normal neurological processes as well as in diseases.